Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Cetuximab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
cancer erbitux kras egfr treatment colorectal head neck receptor antibody indicated drug merck metastatic use chimeric mouse human intravenous medical
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Cetuximab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Cetuximab | ATC code | L01FE01 (WHO) | 1.00 | infobox |
| Cetuximab | CAS Number | 205923-56-4 Y | 1.00 | infobox |
| Cetuximab | ChEMBL | ChEMBL1201577 N | 1.00 | infobox |
| Cetuximab | ChemSpider | none | 1.00 | infobox |
| Cetuximab | CompTox Dashboard (EPA) | DTXSID0040830 | 1.00 | infobox |
| Cetuximab | DrugBank | DB00002 Y | 1.00 | infobox |
| Cetuximab | Elimination half-life | 114 hrs | 1.00 | infobox |
| Cetuximab | Formula | C6484H10042N1732O2023S36 | 1.00 | infobox |
| Cetuximab | KEGG | D03455 Y | 1.00 | infobox |
| Cetuximab | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Cetuximab | Legal status | CA: ℞-only | 1.00 | infobox |
| Cetuximab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Cetuximab | Legal status | US: ℞-only | 1.00 | infobox |
| Cetuximab | Legal status | EU: Rx-only | 1.00 | infobox |
| Cetuximab | License data | US DailyMed: Cetuximab | 1.00 | infobox |
| Cetuximab | Molar mass | 145781.92 g·mol−1 | 1.00 | infobox |
| Cetuximab | Pregnancy category | AU: D | 1.00 | infobox |
| Cetuximab | Routes of administration | Intravenous | 1.00 | infobox |
| Cetuximab | Source | Chimeric (mouse/human) | 1.00 | infobox |
| Cetuximab | Target | EGF receptor | 1.00 | infobox |
| Cetuximab | Trade names | Erbitux | 1.00 | infobox |
| Cetuximab | Type | Whole antibody | 1.00 | infobox |
| Cetuximab | UNII | PQX0D8J21J | 1.00 | infobox |
| Cetuximab | is a | chimeric | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.